SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000947871-20-000158
Filing Date
2020-02-27
Accepted
2020-02-27 17:12:45
Documents
2
Period of Report
2020-02-24

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1638
2 POWER OF ATTORNEY ss167177_ex2401.htm EX-24.1 7020
  Complete submission text file 0000947871-20-000158.txt   10299
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Issuer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD. 190 ELGIN AVENUE GEORGE TOWN E9 KYI-9007
Business Address C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD. 190 ELGIN AVENUE GEORGE TOWN E9 KYI-9007 962 6 582 7999
GMS Ventures & Investments (Reporting) CIK: 0001804598 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37759 | Film No.: 20663697